ASSIGNMENT AND NOVATION AGREEMENTAssignment and Novation Agreement • August 7th, 2020 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS ASSIGNMENT AND NOVATION AGREEMENT (this “Assignment Agreement”) is made as of July 31, 2020 (“Assignment Date”), by and among Vir Biotechnology, Inc., a Delaware corporation having a principal place of business at 499 Illinois Street, Suite 500, San Francisco, CA 94158 U.S.A (“Assignor”), GlaxoSmithKline Trading Services Limited, a company registered in Ireland under company number 406466 having a principal place of business at 980 Great West Road, Brentford, Middlesex, TW8 9GS, England, (“Assignee”), and Samsung BioLogics Co., Ltd., a Republic of Korean company having a principal place of business at 300, Songdo bio-daero, Yeonsu-gu, Incheon 21987 Republic of Korea (“Supplier”). Assignor, Assignee and Supplier are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
ASSIGNMENT AND NOVATION AGREEMENTAssignment and Novation Agreement • August 7th, 2020 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS ASSIGNMENT AND NOVATION AGREEMENT (this “Agreement”) is made as of July 29, 2020 (“Assignment Date”), by and among Vir Biotechnology, Inc., a Delaware corporation having a principal place of business at 499 Illinois Street, Suite 500, San Francisco, CA 94158 U.S.A (“Assignor”), GlaxoSmithKline Trading Services Limited, a company registered in Ireland under company number 406466 having a principal place of business at 980 Great West Road, Brentford, Middlesex, TW8 9GS, England, (“Assignee”), and WuXi Biologics (Hong Kong) Limited with offices located at Flat/RM826, 8/F Ocean Centre Harbour City, 5 Canton Road TST, Hong Kong (“Provider”). Assignor, Assignee and Provider are hereinafter referred to individually as a “Party” and collectively as the “Parties”.
